Genotype-first analysis redefines autosomal dominant LZTR1-related disorders susceptibility architecture

LZTR1 -associated syndromes have defined the clinical recognition of this gene, yet its population susceptibility architecture remains unclear. Here we combined population-scale variant data, systematic literature curation, standardized ACMG/AMP interpretation, and allele-frequency modeling to evaluate dominant LZTR1 -associated susceptibility using a genotype-first framework. We analyzed 4,930 LZTR1 variants from gnomAD and curated 181 reported variants from 50 publications. Pathogenic and likely pathogenic variants were distributed across functional domains without strict syndrome-specific segregation and were collectively more frequent in population datasets than expected for a condition recognized mainly through rare syndrome-based ascertainment. Allele-frequency modeling predicted a population prevalence of approximately 2.5 to 2.8 per 1,000, depending on modeling assumptions, for dominant LZTR1 -associated susceptibility. These results reveal a substantial gap between variant frequency and clinical recognition, support a model of dominant LZTR1 -associated susceptibility as a common, variably penetrant Mendelian susceptibility state, and illustrate how genotype-first approaches can refine disease architecture beyond syndrome-based classification.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-09-16
DOI
https://doi.org/10.1038/s41598-026-71395-4
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Genotype-first analysis redefines autosomal dominant LZTR1-related disorders susceptibility architecture

Shelley S. Noland, Maciej M. Mrugała, Bernard R. Bendok, Mohammad Karam Chaaban et al.
Scientific Reports
Genomics and Rare Diseases
article

Genotype-first analysis redefines autosomal dominant LZTR1-related disorders susceptibility architecture

Shelley S. Noland, Maciej M. Mrugała, Bernard R. Bendok, Mohammad Karam Chaaban, David M. Melville, Linnea M. Baudhuin, Bukola A. Olarewaju, Alyx B. Porter, Hussein Abdul Nabi, Misha Asif, Majd Chaaban, Mark Pittelkow, Yaqqira Womack, Fadi Shamoun, Marlene Girardo, Dusica Babovic-Vuksanovic, Mayowa A. Osundiji, Kristina R. Dandurand, Ehab Harahsheh, Radhika Dhamija, Masoud Hayatdavoodi, Meghan H. Carr
article en

Abstract

LZTR1 -associated syndromes have defined the clinical recognition of this gene, yet its population susceptibility architecture remains unclear. Here we combined population-scale variant data, systematic literature curation, standardized ACMG/AMP interpretation, and allele-frequency modeling to evaluate dominant LZTR1 -associated susceptibility using a genotype-first framework. We analyzed 4,930 LZTR1 variants from gnomAD and curated 181 reported variants from 50 publications. Pathogenic and likely pathogenic variants were distributed across functional domains without strict syndrome-specific segregation and were collectively more frequent in population datasets than expected for a condition recognized mainly through rare syndrome-based ascertainment. Allele-frequency modeling predicted a population prevalence of approximately 2.5 to 2.8 per 1,000, depending on modeling assumptions, for dominant LZTR1 -associated susceptibility. These results reveal a substantial gap between variant frequency and clinical recognition, support a model of dominant LZTR1 -associated susceptibility as a common, variably penetrant Mendelian susceptibility state, and illustrate how genotype-first approaches can refine disease architecture beyond syndrome-based classification.

Scientific Reports
Niagara College (CA), Mayo Clinic (US), University of Dundee (GB), WinnMed (US), Regional Municipality of Niagara (CA), Medication Management (United States) (US), Mayo Clinic in Arizona (US), Mayo Clinic Hospital (US), Mayo Clinic in Florida (US), Damascus University (SY)
Children's Tumor Foundation
Openalex Percentile: Top 11%
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.